Triamcinolone Acetonide Extended-Release Injectable Suspension has 17 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Amphotericin B, Anticholinesterase Agents, Cyclosporine. Patients taking Triamcinolone Acetonide Extended-Release Injectable Suspension should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 17
- Major
- 3
- Moderate
- 14
Major (3)
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Amphotericin B— Concomitant use with corticosteroids may cause hypokalemia and cases of cardiac enlargement and congestive heart failure…
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Anticholinesterase Agents— Concomitant use with corticosteroids may produce severe weakness in patients with myasthenia gravis.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Cyclosporine— Increased activity of both drugs may occur concurrently; convulsions have been reported with concurrent use.
Moderate (14)
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Acetylsalicylic Acid— Concomitant use increases risk of gastrointestinal side effects; use cautiously in hypoprothrombinemia.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Acidifying Agents— Corticosteroids may increase blood glucose concentrations; dosage adjustments of antidiabetic agents may be required.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Aminoglutethimide— Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Barbiturates— CYP 3A4 inducers enhance metabolism of corticosteroids and may require dosage increase.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Carbamazepine— CYP 3A4 inducer enhances metabolism of corticosteroids and may require dosage increase.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Cholestyramine Light— Cholestyramine may increase the clearance of corticosteroids.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Digitalis Glycosides— Patients may be at increased risk of arrhythmias due to corticosteroid-induced hypokalemia.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Estrogens— Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Isoniazid— Serum concentrations of isoniazid may be decreased with concurrent corticosteroid use.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Ketoconazole— CYP 3A4 inhibitors (e.g., ketoconazole) Ketoconazole, a strong CYP3A4 inhibitor, has been reported to decrease the metab…
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Macrolide Antibiotics— Macrolide antibiotics cause a significant decrease in corticosteroid clearance.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Phenytoin— CYP 3A4 inducer enhances metabolism of corticosteroids and may require dosage increase.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Rifampin— CYP 3A4 inducer enhances metabolism of corticosteroids and may require dosage increase.
- Triamcinolone Acetonide Extended-Release Injectable Suspension + Warfarin— Coadministration usually results in inhibition of response to warfarin; monitor coagulation indices frequently.